Generic Levulan Kerastick Availability

Last updated on Jun 11, 2025.

Levulan Kerastick is a brand name of aminolevulinic acid topical, approved by the FDA in the following formulation(s):

LEVULAN (aminolevulinic acid hydrochloride - solution;topical)

• Manufacturer: SUN PHARM INDS INC
  Approval date: December 3, 1999
  Strength(s): 20% ^[RLD]

Is there a generic version of Levulan Kerastick available?

No. There is currently no therapeutically equivalent version of Levulan Kerastick available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Levulan Kerastick. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Methods for photodynamic therapy
  Patent 10,357,567
  Issued: July 23, 2019
  Inventor(s): Lundahl Scott & Guttadauro Michael
  Assignee(s): DUSA Pharmaceuticals, Inc.
  

  A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

  Patent expiration dates:

  • January 12, 2038
    
    ✓ 
    Patent use: TREATMENT OF ACTINIC KERATOSIS OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY
• Methods for photodynamic therapy
  Patent 11,077,192
  Issued: August 3, 2021
  Inventor(s): Lundahl Scott & Guttadauro Michael
  Assignee(s): DUSA PHARMACEUTICALS, INC.
  

  A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

  Patent expiration dates:

  • January 12, 2038
    
    ✓ 
    Patent use: TREATMENT OF ACTINIC KERATOSIS OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY
• Methods for photodynamic therapy
  Patent 11,135,293
  Issued: October 5, 2021
  Inventor(s): Lundahl Scott & Guttadauro Michael
  Assignee(s): DUSA PHARMACEUTICALS, INC.
  

  A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

  Patent expiration dates:

  • January 12, 2038
    
    ✓ 
    Patent use: TREATMENT OF ACTINIC KERATOSIS OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY
• Method of administering 5-aminolevulinic acid (ALA) to a patient
  Patent 11,179,574
  Issued: November 23, 2021
  Inventor(s): Boyajian; Thomas et al.
  Assignee(s): DUSA PHARMACEUTICALS, INC. (Billerica, MA)
  

  A method of administering 5-aminolevulinic acid (ALA) to a patient uses an adjustable illuminator for photodynamically diagnosing or treating a surface and which includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

  Patent expiration dates:

  • October 13, 2036
    
    ✓ 
    Patent use: TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
• Adjustable illuminator for photodynamic therapy and diagnosis
  Patent 11,446,512
  Issued: September 20, 2022
  Inventor(s): Boyajian; Thomas et al.
  Assignee(s): DUSA PHARMACEUTICALS, INC. (Billerica, MA)
  

  An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

  Patent expiration dates:

  • January 17, 2037
    
    ✓ 
    Patent use: TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
• Methods for photodynamic therapy
  Patent 11,571,478
  Issued: February 7, 2023
  Inventor(s): Lundahl; Scott et al.
  Assignee(s): DUSA PHARMACEUTICALS, INC. (Billerica, MA)
  

  A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

  Patent expiration dates:

  • January 12, 2038
    
    ✓ 
    Patent use: TREATMENT OF ACTINIC KERATOSIS OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY
• Methods for photodynamic therapy
  Patent 11,690,914
  Issued: July 4, 2023
  Inventor(s): Lundahl; Scott et al.
  Assignee(s): DUSA Pharmaceuticals, Inc. (Billerica, MA)
  

  A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

  Patent expiration dates:

  • January 12, 2038
    
    ✓ 
    Patent use: TREATMENT OF ACTINIC KERATOSIS OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY
• Adjustable illuminator for photodynamic therapy and diagnosis
  Patent 11,697,028
  Issued: July 11, 2023
  Inventor(s): Boyajian; Thomas et al.
  Assignee(s): DUSA PHARMACEUTICALS, INC. (Billerica, MA)
  

  An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

  Patent expiration dates:

  • October 13, 2036
    
    ✓ 
    Patent use: TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
• Adjustable illuminator for photodynamic therapy and diagnosis
  Patent 12,290,700
  Issued: May 6, 2025
  Inventor(s): Boyajian; Thomas et al.
  Assignee(s): Sun Pharmaceutical Industries, Inc. (Princeton, NJ)
  

  An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

  Patent expiration dates:

  • October 13, 2036
    
    ✓ 
    Patent use: TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
• Methods for photodynamic therapy
  Patent 12,296,011
  Issued: May 13, 2025
  Inventor(s): Lundahl; Scott et al.
  Assignee(s): Sun Pharmaceutical Industries, Inc. (Princeton, NJ)
  

  A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

  Patent expiration dates:

  • January 12, 2038
    
    ✓ 
    Patent use: TREATMENT OF ACTINIC KERATOSIS OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer